Journal
MULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume 6, Issue -, Pages 49-53Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2016.01.001
Keywords
Intrathecal rituximab; biomarkers; B-cells; CD20+; CD19+; BAFF
Categories
Funding
- MRC
- National MS Society
- MS Society of Great Britain and Northern Ireland
- AIMS2CURE
- Roan Charitable Trust
Ask authors/readers for more resources
Objectives: Clinical trials of IV-rituximab have proved successful. It is unclear whether intrathecal (IT)rituximab is more efficacious at lower doses. We examine its effects on B-cell biomarkers. Methods: MS patients received IT-rituximab at 3 time-points. CSF and serum samples were obtained at up to 5 time-points (days 0, 7, 14, 56 and 112). Serum and CSF BAFF and CXCL13, and CSF kappa and lambda free light chains (FLC) were measured. Flow cytometry was performed, examining effects on lymphocytes, CD3-19+ and CD3-20+ cells. Results: CSF BAFF fell following rituximab (p = 0.0091 absolute values, p = 0.0284 change from baseline) whilst serum BAFF increased across time-points 1-4 (p = 0.0005 absolute values, p = 0.0017 change from baseline). There were significant reductions in CD20+ and CD19+ cells in blood from baseline (p < 0.0001) but not in CSF. CSF kappa FLC levels significantly increased (p = 0.0480). Conclusions: BAFF levels fall in CSF but increase in serum following IT-rituximab. Rituximab appears to act peripherally with dramatic decreases in peripheral CD20+ and CD19+ cells. It is likely that CSF B-cell counts were too low to enable differences to be seen. The rapid reduction in B-cells suggests rituximab has immediate effects. The profound depletion of B-cells, despite low doses of rituximab, underlines rituximab's efficacy. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available